Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Authors
Keywords
-
Journal
LEUKEMIA
Volume 32, Issue 7, Pages 1561-1566
Publisher
Springer Nature
Online
2018-02-02
DOI
10.1038/s41375-018-0017-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
- (2017) S S Chavan et al. Blood Cancer Journal
- The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
- (2017) Caleb K. Stein et al. Oncotarget
- Progress in the treatment of ovarian cancer—lessons from homologous recombination deficiency—the first 10 years
- (2016) S. B. Kaye ANNALS OF ONCOLOGY
- Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma
- (2016) S Mithraprabhu et al. LEUKEMIA
- The Current Status of PARP Inhibitors in Ovarian Cancer
- (2016) Jennifer McLachlan et al. TUMORI
- The Current Status of PARP Inhibitors in Ovarian Cancer
- (2016) Jennifer McLachlan et al. TUMORI JOURNAL
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
- (2015) D. A. Alagpulinsa et al. MOLECULAR CANCER THERAPEUTICS
- Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
- (2015) Rohit Prakash et al. Cold Spring Harbor Perspectives in Biology
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
- (2014) L Melchor et al. LEUKEMIA
- Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
- (2014) T Paíno et al. LEUKEMIA
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
- (2014) Niccolo Bolli et al. Nature Communications
- Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
- (2013) B A Walker et al. LEUKEMIA
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors
- (2011) P. Neri et al. BLOOD
- A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
- (2010) B. A. Walker et al. BLOOD
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
- (2010) D. Hose et al. HAEMATOLOGICA
- BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors
- (2010) Jurgen Veeck et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started